Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Clinical perspectives of BET inhibition in ovarian cancer — Αngeliki Andrikopoulou (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Clinical perspectives of BET inhibition in ovarian cancer
Shared by
Meletios A Dimopoulos
Clinical perspectives of BET inhibition in ovarian cancer
Article
2021
en
Authors
+2 more
ΑA
Αngeliki Andrikopoulou
ML
Michalis Liontos
KK
Konstantinos Koutsoukos
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2020
Clinical Perspectives of ERCC1 in Bladder Cancer
Konstantinos Koutsoukos
,
Αngeliki Andrikopoulou
,
Nikos Dedes
,
Flora Zagouri
,
Aristotelis Bamias
,
Meletios A Dimopoulos
Article
2025
Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives
N Dedes
,
Michalis Liontos
,
Dimitrios Haidopoulos
,
Flora Zagouri
,
Kyveli Angelou
,
Anna Svarna
,
Athanasios Michas
,
Aikaterini Aravantinou Fatorou
,
Αngeliki Andrikopoulou
,
Meletios A Dimopoulos
Article
2020
The emerging role of BET inhibitors in breast cancer
Αngeliki Andrikopoulou
,
Michalis Liontos
,
Konstantinos Koutsoukos
,
Meletios A Dimopoulos
,
Flora Zagouri
Article
1984
The clinical relevance of the epidemiology of ovarian cancer
Carlo La Vecchia
,
Silvia Franceschi
,
A. Liberati
,
Giuseppe Gallus
,
Gianni Tognoni
Article
2020
Genetic and clinical analysis of epithelial ovarian cancer in Greek patients
Nikolas Plevris
,
Pappa KI
,
G. Tsironis
,
M. Liontos
,
Ekatherina Charvalos
,
Alexandros Rodolakis
,
G. Vlachos
,
Meletios A Dimopoulos
,
Flora Zagouri
,
Paraskevi Apostolou
,
Irene Konstantopoulou
,
D Yanoukakos
,
Florentia Fostira
Discussion(0)
No comments yet. Be the first to comment.